PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Intestinal Research10.5217/ir.2020.000262021194448-460Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitisTaku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibihttp://irjournal.org/upload/pdf/ir-2020-00026.pdf, http://irjournal.org/journal/view.php?doi=10.5217/ir.2020.00026, http://irjournal.org/upload/pdf/ir-2020-00026.pdf
Drugs & Therapy Perspectives10.1007/s40267-021-00873-820213712563-572Subcutaneous vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a profile of its useSheridan M. Hoyhttps://link.springer.com/content/pdf/10.1007/s40267-021-00873-8.pdf, https://link.springer.com/article/10.1007/s40267-021-00873-8/fulltext.html, https://link.springer.com/content/pdf/10.1007/s40267-021-00873-8.pdf
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy10.1002/phar.165120153510979-979Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitishttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fphar.1651, https://onlinelibrary.wiley.com/doi/full/10.1002/phar.1651
BioDrugs10.1007/s40259-014-0113-2201429157-67Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s DiseaseK. P. Garnock-Joneshttp://link.springer.com/content/pdf/10.1007/s40259-014-0113-2.pdf, http://link.springer.com/article/10.1007/s40259-014-0113-2/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40259-014-0113-2
Journal of Crohn's and Colitis10.1093/ecco-jcc/jjab076.551202115Supplement_1S431-S432P427 Efficacy and safety of vedolizumab and adalimumab in Asian adults with moderately to severely active ulcerative colitis: Post-hoc analysis of the VARSITY trialJ S Kim, W K Leung, D C Wu, D Lindner, O Fadeeva, D Demuthhttp://academic.oup.com/ecco-jcc/article-pdf/15/Supplement_1/S431/38321420/jjab076.551.pdf, http://academic.oup.com/ecco-jcc/article-pdf/15/Supplement_1/S431/38321420/jjab076.551.pdf
Value in Health10.1016/j.jval.2017.08.14382017209A635Cost-Effectiveness of Vedolizumab for the Treatment of Adult Patients with Moderately-to-Severely Active Ulcerative Colitis in RussiaE Pyadushkina, EV Derkachhttps://api.elsevier.com/content/article/PII:S1098301517317722?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301517317722?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(16)30545-520161504S132631 A Multi-Center Open-Label Study Assessing Pharmacokinetics, Efficacy, and Safety of Subcutaneous Golimumab in Pediatric Patients With Moderately-Severely Active Ulcerative ColitisJeffrey S. Hyams, Anne M. Griffiths, Gigi Veereman, Dan Turner, Daphne Chan, Omoniyi J. Adedokun, Lakshmi Padgett, Rick Strausshttps://api.elsevier.com/content/article/PII:S0016508516305455?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508516305455?httpAccept=text/plain
BioDrugs10.1007/s40259-015-0115-8201529173-73Erratum to: Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s DiseaseK. P. Garnock-Joneshttp://link.springer.com/content/pdf/10.1007/s40259-015-0115-8.pdf, http://link.springer.com/article/10.1007/s40259-015-0115-8/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40259-015-0115-8
Yearbook of Gastroenterology10.1016/s0739-5930(09)79361-420092009110-111Safety and Efficacy of a New 3.3g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled StudyM.F. Piccohttps://api.elsevier.com/content/article/PII:S0739593009793614?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0739593009793614?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(22)61422-720221627S-602Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISMarla C. Dubinsky, Keith Betts, Devrim Eren, Wenxi Tang, Lei Yin, Komal Gupte-Singhhttps://api.elsevier.com/content/article/PII:S0016508522614227?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508522614227?httpAccept=text/plain